Prosecution Insights
Last updated: April 19, 2026

Leason Ellis LLP (Genentech)

7 pending office actions • 2 clients

Portfolio Summary

7
Total Pending OAs
1
Final Rejections
6
Non-Final OAs

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Poseida Therapeutics, Inc. 5
Genentech, Inc. 2

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
19285781 COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS Genentech, Inc. WEN, SHARON X 1641 Non-Final OA Jul 30, 2025
18264782 GENETICALLY MODIFIED INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE THEREOF Poseida Therapeutics, Inc. GOMEZ RODRIGUEZ, JULIO WASHINGTON 1637 Non-Final OA Aug 09, 2023
18351442 COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS Poseida Therapeutics, Inc. CARTER, SANDRA DILLAHUNT 1674 Non-Final OA Jul 12, 2023
17996021 COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF CANCER Poseida Therapeutics, Inc. WEHBE, ANNE MARIE SABRINA 1634 Non-Final OA Jun 16, 2023
18334531 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS Genentech, Inc. OUSPENSKI, ILIA I 1644 Non-Final OA Jun 14, 2023
18051109 HYPERACTIVE PIGGYBAC TRANSPOSASES Poseida Therapeutics, Inc. NOAKES, SUZANNE MARIE 1656 Non-Final OA Oct 31, 2022
16977547 CARTYRIN COMPOSITIONS AND METHODS FOR USE Poseida Therapeutics, Inc. ALLEN, MICHAEL D 1671 Final Rejection Sep 02, 2020

Managing Leason Ellis LLP (Genentech)'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month